Table 2.
Demographic and clinical characteristics of the study group, depending on the line of disease-modifying therapy.
| Parameters | LI | LII | CGj | p |
|---|---|---|---|---|
| N | 44 | 19 | 10 | — |
| DMTa [n] | IF1a/IF1bf/GAg | NTh/FGi | — | — |
| 22/17/5 | 7/12 | |||
| Age [years] | 43.5 ± 11.4 | 39.2 ± 12.4 | — | 0.11 |
| Age at the beginning of DMT [years] | 40.9 ± 11.2 | 37.6 ± 12.2 | 39.3 ± 2.47 | 0.23 |
| Age [% of females] | 72.7 | 68.4 | 60.0 | 0.72 |
| Time of MS [months] | 72.0 ± 52.4 | 87.8 ± 31.1 | — | 0.048 |
| Time of DMT [months] | 29.9 ± 14.9 | 17.9 ± 7.1 | — | 0.005 |
| EDSSb [score] | 2.48 ± 0.98 | 2.97 ± 1.17 | — | 0.10 |
| ARRc [n] | 0.36 ± 0.57 | 0.32 ± 0.67 | — | 0.51 |
| T2 MRId lesions (from the time of diagnosis) [n] | 1.14 ± 0.41 | 1.05 ± 0.23 | — | 0.45 |
| New MRI lesions (within the last year) [n] | 0.09 ± 0.29 | 0.21 ± 0.54 | — | 0.42 |
| Gd+e MRI lesions (from the time of diagnosis) [n] | 2.39 ± 15.2 | 0.53 ± 1.43 | — | 0.60 |
| New Gd+ MRI lesions (within the last year) [n] | 0.07 ± 0.25 | 0.53 ± 1.43 | — | 0.24 |
A: disease-modifying therapy; b: Expanded Disability Status Scale; c: annual relapse rate; d: magnetic resonance imaging; e: Gadovist; f: interferon beta; g: glatiramer acetate; h: natalizumab; i: fingolimod; j: control group.